EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX: NBY, www.novabaypharma.com) reports that the United States Patent and Trademark Office has approved the issuance of U.S. Patent No. 7,462,361 to NovaBay for novel Aganocide compounds including its current lead compound, NVC-422 (N,N-dichloro-2,2-dimethyltaurine). The patent will expire on April 24, 2026.
